论文部分内容阅读
[目的]观察放疗前新辅助化疗对于宫颈癌的预后的影响及临床疗效。[方法]选取2008年6月～2010年9月接受治疗的116例宫颈癌患者,接受放射治疗前给以DP(多西紫杉醇联合顺铂)方案的新辅助化疗,化疗2个周期再给予根治性放疗后评价疗效。[结果]总有效率84.5%,CR31.0%(36/116),PR53.4%(62/116),SD13.8%(16/116),PD1.7%(2/116),其中ⅡB期有效率(CR+PR)为100.0%(18/18),ⅢA期有效率为100%(22/22),ⅢB期有效率为94.8%(55/58);ⅣA期有效率为23.1%(3/13);ⅣB期有效率为0(0/5)。[结论]放疗前新辅助化疗可以有效地控制病灶,减少病灶转移,改善患者生活质量,改善预后。
[Objective] To observe the effect of neoadjuvant chemotherapy before radiotherapy on the prognosis of cervical cancer and its clinical efficacy. [Method] A total of 116 cervical cancer patients who were treated from June 2008 to September 2010 were treated with neoadjuvant chemotherapy with DP (docetaxel combined with cisplatin) before radiotherapy. Radiotherapy was given to two cycles of chemotherapy Evaluation of efficacy after radiotherapy. [Results] The total effective rate was 84.5%, CR31.0% (36/116), PR53.4% (62/116), SD13.8% (16/116) and PD1.7% (2/116) The effective rate of stage Ⅱ B was 100.0% (18/18), that of stage ⅢA was 100% (22/22), that of stage Ⅲ B was 94.8% (55/58), that of stage ⅣA was 23.1 % (3/13); ⅣB effective rate of 0 (0/5). [Conclusion] Neoadjuvant chemotherapy before radiotherapy can effectively control the lesion, reduce the metastasis of the lesion, improve the quality of life of patients and improve the prognosis.